Oct 12, 2021 / 07:30PM GMT
Patrick Trucchio - H.C. Wainwright & Co., LLC - Analyst
My name is Patrick Trucchio, and I am a Senior Biotech Analyst at H.C. Wainwright. It's my pleasure to introduce our next presenters, Vipin Garg, CEO; and Scott Harris, Chief Medical Officer of Altimmune, a clinical stage biopharmaceutical company focusing on developing treatments for obesity and liver disease. So I think maybe just to start, if we could talk about Altimmune's synthetic peptide technology platform, how did this come to be in its current form and what makes it differentiated from others in the market?
Vipin Garg - Altimmune, Inc. - President & CEO
Yes. Thanks, Patrick. Thank you for having us. So as you know, we are developing two different therapeutic candidates, both peptide-based, based on synthetic peptide platform technology, and we have made specific modifications to this peptide -- to these peptides to accomplish a specific goal. For instance, to increase half-life of the peptide molecule. So our first candidate is ALT-801, or Pemvidutide. It is a GLP-1 glucagon dual agonist
Altimmune Inc at H C Wainwright NASH Investor Conference (Virtual) Transcript
Oct 13, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers